Tenax Therapeutics (TENX) Stock Forecast & Price Target

Tenax Therapeutics is viewed positively because LEVEL was well-conducted and well-powered, and while the overall 6MWT treatment difference was only 3.5m with no KCCQ benefit, a +26.3m subgroup signal in patients below the median baseline 6MWT suggests levo may still have meaningful efficacy in sicker patients with limited options. The strong NT-proBNP reduction of -49% versus placebo, along with the potential for more informative baseline and hemodynamic analyses, supports a plausible path forward even as commercial implications remain unclear. Although discontinuations, dose reductions, frequent adverse events, and two deaths versus none on placebo create regulatory headwinds and lower the PoS to 25% from 80%, the same uncertainty also implies that successful patient selection could unlock a narrower but still attractive market opportunity.

Tenax Therapeutics is facing a fundamentally weak risk-reward profile because its LEVEL phase III study missed the primary endpoint and key secondary endpoints, with 6MWD at Week 12 showing only a 3.5m treatment difference versus placebo and a p-value of 0.63. The failure sharply raises the probability that the company cannot demonstrate clinically meaningful and statistically significant efficacy in Phase 3, while also worsening an already difficult regulatory path that may require two positive studies under FDA expectations. Despite IP protection into 2040 and some potential market opportunity, the company still faces trial delays, possible narrow approvals, and competitive threats from sotatercept and relaxin, all of which reinforce a negative outlook.